| Malignant neoplasm of prostate
Firmagon vs Trelstar
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of prostate.Deep comparison between: Firmagon vs Trelstar with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrelstar has a higher rate of injection site reactions vs Firmagon based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trelstar but not Firmagon, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Firmagon
Trelstar
At A Glance
SC injection
Every 28 days
GnRH receptor antagonist
IM injection
Every 4-24 weeks
GnRH agonist
Indications
- Malignant neoplasm of prostate
- Malignant neoplasm of prostate
Dosing
Malignant neoplasm of prostate Starting dose: 240 mg given as two SC injections of 120 mg each at 40 mg/mL; maintenance dose: 80 mg given as one SC injection at 20 mg/mL every 28 days beginning 28 days after the starting dose.
Malignant neoplasm of prostate 3.75 mg by single IM injection every 4 weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks; strengths are not additive and must be selected based on the desired dosing schedule.
Contraindications
- History of severe hypersensitivity to degarelix or any product component
- Known hypersensitivity to triptorelin or any other component of the product, or other GnRH agonists or GnRH
Adverse Reactions
Most common (>=10%) Injection site reactions (pain, erythema, swelling, induration), hot flashes, increases in serum transaminases and GGT
Postmarketing Decreased bone density
Most common (>=1%) Hot flush, skeletal pain, headache, impotence/erectile dysfunction, hypertension, injection site pain, edema, dysuria, urinary tract infection, insomnia
Serious Tumor flare, hypersensitivity reactions, metabolic syndrome, cardiovascular disease, convulsions, severe cutaneous adverse reactions, QT/QTc prolongation, spinal cord compression
Postmarketing Pituitary apoplexy, cerebrovascular accident, myocardial infarction, pulmonary emboli, thromboembolic events, convulsions, non-alcoholic fatty liver disease, interstitial lung disease, SJS/TEN, DRESS, AGEP, erythema multiforme
Pharmacology
GnRH receptor antagonist; degarelix binds reversibly to pituitary GnRH receptors, reducing the release of gonadotropins and consequently suppressing testosterone below the castration level of 50 ng/dL.
Triptorelin is a synthetic decapeptide GnRH agonist; chronic continuous administration suppresses LH and FSH secretion and markedly reduces testicular steroidogenesis, achieving medical castration levels of testosterone in men with advanced prostate cancer.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Firmagon
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (10/12)
Trelstar
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Firmagon
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (2/8)
Trelstar
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Firmagon
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Trelstar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FirmagonView full Firmagon profile
TrelstarView full Trelstar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.